About this site

What Legit KLOW is

Legit KLOW is an independent editorial project that publishes summaries of the peer-reviewed research literature on KLOW peptide and its four constituent compounds — KPV, GHK-Cu, BPC-157 and TB-500. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'legit' in the name is a deliberate editorial stance: a commitment to cite every claim, to attribute each finding to the specific component it belongs to, and to leave the combination data gap — where no controlled blend study exists — in plain sight as the most important fact on the site. We do not paper over that absence.

The domain modifier 'legit' is editorial framing — a commitment to a standard of citation and attribution — not a claim about the site's regulatory status, staffing, or services. This site has no clinical staff, no physical location, and no healthcare services.

How we handle the literature

Every quantitative claim on this site is cited to a numbered reference in the KLOW references list. Findings are attributed to the specific component they belong to — a rat wound study for thymosin beta-4 is cited as a thymosin beta-4 / TB-500 finding, not as a KLOW blend finding. The blend's combination record is a blank, and it is presented as such.

We use the following hierarchy:

1. Peer-reviewed published studies (PubMed, PMC, DOI-indexed journals)
2. Preprints and non-peer-reviewed reports, clearly labeled
3. Community/anecdotal accounts, always labeled 'anecdotal, not clinical evidence'

Anecdotal reports on the effects page carry the label clearly and are not cited as evidence of efficacy.

KLOW peptide buy: this site does not sell KLOW, link to vendors, or provide sourcing guidance. The transactional dimension of KLOW is outside our editorial scope.

Scope and limitations

This site covers the research literature as it stands at publication. The KLOW component literature is active — GHK-Cu in particular has recent 2024–2025 reviews and mechanistic studies. We update the record as material new findings are published.

We do not cover: pricing, sourcing, stacking with other compounds (beyond brief context references), personal experience accounts, or any clinical recommendations. We do not provide medical advice or suggest that any information on this site should influence a healthcare decision.

For any health question, consult a qualified healthcare provider. For any anti-doping question — given that TB-500/thymosin beta-4 is WADA-prohibited — consult the World Anti-Doping Agency or your national anti-doping organization.